Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688712 · ClinicalTrials.gov registry record · Phase 2
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
A Phase 2 study of Rectal Adenocarcinoma, sponsored by Providence Health & Services.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02688712 is a Phase 2 study of Rectal Adenocarcinoma that is active but no longer recruiting, run by Providence Health & Services. The registered enrollment target is 50 participants, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02688712, a Phase 2 study of Rectal Adenocarcinoma, is active but no longer recruiting, sponsored by Providence Health & Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possible to predict if patients will respond to treatment, and blood samples to look at the immune system response to study treatment. About 50 people will take part in this study. The study treatment will be given over an 8 week period and the investigators will continue to collect your health information for up to 5 years, as part of this study
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Fluorouracil
- DRUG LY2157299
- PROCEDURE Tumor specific mesorectal excision
Study Locations (1)
Oregon
- Providence Cancer Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-03-24 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02688712
The ClinicalTrials.gov registry entry for NCT02688712 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (59% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT02688712 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02688712 about?
NCT02688712 is a clinical study titled "ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer". The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possible to predict if patients will respond to treatme...
What is the current status of trial NCT02688712?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-03-24. Estimated completion is 2025-12.
What conditions does trial NCT02688712 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma.
What interventions are being tested in trial NCT02688712?
The interventions under investigation include: Capecitabine (DRUG), Fluorouracil (DRUG), LY2157299 (DRUG), Tumor specific mesorectal excision (PROCEDURE).
Who is sponsoring clinical trial NCT02688712?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02688712 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
RECRUITING · Phase 2
-
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
RECRUITING · Phase 2
-
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.